Company Description
Although it's based in neutral Switzerland, Novartis has been aggressive in attacking illnesses on four fronts: pharmaceuticals, vaccines and...
Key Novartis Financials
| Company Type | Public - NYSE: NVS; Swiss: NVS Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $38,947.0 |
| 2007 Employees | 98,200 |
More Novartis Financials (11 pages)
Latest Novartis Jobs powered by Monster.com
- Protein Design Scientists & Managers
- Associate Director Health Economics and Outcomes Research
- Pharmaceutical Sales Rep/Consultant- Carrollton, TX 4BAF2A
Rankings
- Dow Jones Global Titans
- Dow Jones STOXX 50
- #30 in FT Global 500
- Swiss Market
Competition
Competitive Landscape for Pharmaceutical Manufacture and Sale
The industry is marked by rapid advances in scientific knowledge that produce ever-more effective medicines. Profitability is determined mainly by the ability to discover new drugs. The industry is...
Read more about Novartis's competition across multiple industries
Top Novartis Competitors
Sponsored Links
The Business DirectoryNovartis Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman and CEO | Daniel L. Vasella | Network | E-mail |
| CFO | Raymond Breu | Network | E-mail |
| Head Human Resources | Juergen Brokatzky-Geiger | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Current Novartis News
- Novartis AG ADR (US$/GAAP) (NVS.GP) Weekly Earnings Information [Nelson Information - Weekly Domestic] (17 May 2008 04:00:00 EDT)
-
Novartis AG ADR (NYSE:NVS) Weekly Earnings Information [Nelson Information - Weekly Domestic] (17 May 2008 04:00:00 EDT) - Market forces: Mixing medicines [Guardian] (17 May 2008 00:01:00 EDT)
Latest Industry Video
-
ASCO 2007 Preview (5:07)
06/01/07 8:50AM ET - Wachovia Capital Markets Senior Biotech Analyst George Farmer and Miller Tabak Pharmaceutical Analyst Les Fundleyder discuss new drugs coming out at this year's conference.





